Ebenbuild has been awarded the European Innovation Council (EIC) received funding of €2.3 million. In addition, the EIC fund is offering up to €10 million for future equity financing. The funding will be used to further develop and scale the company's digital twin platform technology.
A central component of the strategy is the Twinhale software, which digitally simulates drug delivery via the lungs. According to Ebenbuild, Twinhale is the first scalable simulation tool that enables patient-specific, physiologically accurate predictions of drug deposition in the lungs. The target group is pharmaceutical and medical technology companies, who can use the technology to reduce costs, failure rates, and time to market.
Pilot studies successfully completed
Ebenbuild has already used Twinhale in pilot studies with PARI Pharma and Pieris Pharmaceuticals. In a validation study, Twinhale predicted local drug deposition with high accuracy. The software outperformed existing models and enabled design decisions that would not have been possible with in vivo or in vitro testing.
"Our vision is to become the leading health information platform for respiratory diseases. Twinhale is just the beginning. The same core platform will also support future regulated products for optimizing mechanical ventilation and managing chronic respiratory diseases,"
says Dr. Kei Müller, CEO and co-founder of Ebenbuild.
Market entry into CDSS and personalized medicine planned
Ebenbuild plans to enter the markets for clinical decision support systems (CDSS) and personalized medicine in the long term. According to the company, the market potential for these areas is over 300 billion euros by 2030. Today, the Startup active in the global market for in silico studies, which is worth over five billion euros. Ebenbuild is supported by HTGF, Bayern Kapital, and several angel investors.
“With Twinhale, we are not only reducing failure rates in respiratory drug development, but also generating unique data sets that can advance regulatory approval and enable companion diagnostic strategies in the future,”
said Dr. Maximilian Grill, Head of in silico studies at Ebenbuild.
Ebenbuild's product roadmap ranges from preclinical simulations to software solutions for ventilation optimization in patients with pulmonary complications. The current EIC funding is considered non-dilutive capital and validation through one of the most demanding funding programs for tech startups in Europe.
